Quest Diagnostics runs a network of labs in the US, Puerto Rico, Mexico and Brazil, and partners with hospitals worldwide.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
Investors are turning to quality stocks as higher borrowing costs and a slower AI-driven rally reshape the market. Banks and strategists say quality can weather the downturn, with durable earnings, strong balance sheets, and cash flow guiding the next phase. Top analysts highlight hyperscalers and select AI-adopters as key exposures.
Quest Diagnostics has disclosed unauthorized access to its Quanum Lab Services Manager, a platform used by clinicians to order tests and view results. The breach, discovered this week, may involve patient records and personal information and is under investigation. Law enforcement has been notified. Previous Quest breaches and rising cyberattacks in health tech frame the context as investigators pursue specifics.